Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Shanghai Stock Exchange  >  Shanghai Fosun Pharmaceutical Group Co., Ltd.    600196   CNE000000X38

SHANGHAI FOSUN PHARMACEUTICAL GROUP CO., LTD.

(600196)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Shanghai Fosun Pharmaceutical : Fosun International - WHO Adds Fosun Pharma's Covid-19 Test to Its Emergency Use List

share with twitter share with LinkedIn share with facebook
09/14/2020 | 09:27am EDT

Yicai Global - The World Health Organization has inducted one of Shanghai Fosun Pharmaceutical's Covid-19 nucleic acid test kits onto its Emergency Use Listing, which will facilitate the use of the kit by the United Nations and other international organizations fighting Covid-19, the drugmaker said today.

The real-time polymerase chain reaction test kit, developed by unit Shanghai Fosun Long March Medical Science, is stable and highly automated, the Shanghai-based firm said on its WeChat account. It can assay 96 samples within two hours and is safe to use, it added.

The EUL procedure was set up in January to 'expedite the availability of diagnostics in public health emergency situations around the world,' according to the WHO website. 'It will help increase access to quality-assured, accurate tests for the disease,' it added.

Being on the list will hopefully promote the use of the kit in more nations including those in Africa, Fosun said.

This test kit has already been granted licenses by China'sNational Medical Products Administration, Australia'sTherapeutic Goods Administration as well as the European Union. It has also been authorized for emergency use by the US Food and Drug Administration. The firm is exporting to over 10 overseas nations including France, Germany and Belgium, Fosun said.

Fosun Pharma [SHA:600196] closed down 0.62 percent on the mainland today at CNY48.41 (USD7), while its Hong Kong stock [HKG:2196] ended the day down marginally at HKD30.90 (USD4).

Contact:

Email: IR@fosun.com

(C) 2020 Electronic News Publishing, source ENP Newswire


Stocks mentioned in the article
ChangeLast1st jan.
FOSUN INTERNATIONAL LIMITED 0.53% 9.41 End-of-day quote.-17.17%
SHANGHAI FOSUN PHARMACEUTICAL GROUP CO., LTD. -5.40% 52.75 End-of-day quote.98.31%
share with twitter share with LinkedIn share with facebook
All news about SHANGHAI FOSUN PHARMACEUTICAL GROUP CO., LTD.
06:55aSHANGHAI FOSUN PHARMACEUTICAL : Connected transaction - formation of partnership..
PU
10/20SHANGHAI FOSUN PHARMACEUTICAL : Overseas regulatory announcement (h shares)
PU
10/16SHANGHAI FOSUN PHARMACEUTICAL : Date of board meeting (h shares)
PU
10/13SHANGHAI FOSUN PHARMACEUTICAL : Overseas regulatory announcement (h shares)
PU
10/09SHANGHAI FOSUN PHARMACEUTICAL : List of directors and their roles and function (..
PU
10/09SHANGHAI FOSUN PHARMACEUTICAL : Poll results of the resolutions proposed at the ..
PU
10/08Fosun unit to begin U.S. trial of COVID-19 antibody treatment soon
RE
10/08SHANGHAI FOSUN PHARMACEUTICAL : Fosun Pharma Unit Gets FDA Approval for Covid-19..
DJ
10/07SHANGHAI FOSUN PHARMACEUTICAL : Monthly return of equity issuer on movements in ..
PU
09/22SHANGHAI FOSUN PHARMACEUTICAL : Overseas regulatory announcement (h shares)
PU
More news
Financials
Sales 2020 32 760 M 4 905 M 4 905 M
Net income 2020 3 552 M 532 M 532 M
Net Debt 2020 14 860 M 2 225 M 2 225 M
P/E ratio 2020 37,8x
Yield 2020 0,76%
Capitalization 122 B 18 240 M 18 257 M
EV / Sales 2020 4,18x
EV / Sales 2021 3,57x
Nbr of Employees 30 925
Free-Float 62,3%
Chart SHANGHAI FOSUN PHARMACEUTICAL GROUP CO., LTD.
Duration : Period :
Shanghai Fosun Pharmaceutical Group Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SHANGHAI FOSUN PHARMACEUTICAL GROUP CO., LTD.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Average target price 38,35 CNY
Last Close Price 52,75 CNY
Spread / Highest target -0,93%
Spread / Average Target -27,3%
Spread / Lowest Target -59,3%
EPS Revisions
Managers
NameTitle
Yi Fang Wu President, CEO & Executive Director
Qi Yu Chen Co-Chairman
Fang Yao Co-Chairman
Qian Ren Chairman-Supervisory Board
Xiao Hui Guan CFO, Chief Accountant Officer & Senior VP
Sector and Competitors